US Broker Ratings

Disc Medicine, Inc. (IRON) Stock Analysis: Poised for 55% Upside Potential Amid Robust Analyst Confidence

Disc Medicine, Inc. (NASDAQ: IRON), a clinical-stage biopharmaceutical company, is making waves in the biotechnology sector with its innovative approach to addressing serious hematologic diseases. With a market capitalization of..

ICU Medical, Inc. (ICUI) Investor Outlook: Analyzing a 22.82% Potential Upside Amidst Market Volatility

ICU Medical, Inc. (NASDAQ: ICUI) presents a compelling investment narrative within the healthcare sector, specifically in the medical instruments and supplies industry. With a market capitalization of $3.63 billion, the..

Bausch Health Companies Inc. (BHC) Stock Analysis: A Closer Look at Its Potential Upside and Financial Health

Bausch Health Companies Inc. (NYSE: BHC) stands out in the healthcare sector as a diversified specialty pharmaceutical and medical device company. Operating from Laval, Canada, Bausch Health’s market capitalization currently..

Xenon Pharmaceuticals Inc. (XENE) Stock Analysis: Exploring the 24.98% Upside Potential

Xenon Pharmaceuticals Inc. (NASDAQ: XENE) is making waves in the biotechnology sector with a remarkable 24.98% potential upside, capturing the attention of savvy investors looking for promising opportunities in the..

LeMaitre Vascular, Inc. (LMAT) Investor Outlook: A 24.96% Upside Potential Amidst Strong Revenue Growth

LeMaitre Vascular, Inc. (NASDAQ: LMAT), a stalwart in the healthcare sector, particularly in medical instruments and supplies, offers a compelling prospect for investors seeking exposure to the vascular surgery market...

Zai Lab Limited (ZLAB): Analyst Ratings Reveal 175.93% Potential Upside for This Biotech Powerhouse

Zai Lab Limited (NASDAQ: ZLAB), a prominent player in the biotechnology sector, has captured investor attention with its robust pipeline and strategic partnerships. Based in China, Zai Lab focuses on..

HUTCHMED (China) Limited (HCM): Investor Outlook Highlights 68.54% Potential Upside

HUTCHMED (China) Limited (NASDAQ: HCM), a prominent player in the healthcare sector, offers a compelling opportunity for investors seeking exposure to the precision medicine market, particularly in oncology. With its..

Organon & Co. (OGN) Stock Analysis: A Closer Look at Its 31.61% Potential Upside and What It Means for Investors

Organon & Co. (OGN), a prominent player in the healthcare sector specializing in drug manufacturing, presents an intriguing opportunity for investors seeking both stability and potential upside. With a market..

Galapagos NV (GLPG) Stock Analysis: Navigating a 16% Potential Downside Amidst Biotech Innovations

Galapagos NV (Nasdaq: GLPG), a Belgium-based biotechnology firm, stands at a pivotal moment for investors keen on the healthcare sector. With a market capitalization of $2.18 billion, Galapagos is not..

Perrigo Company plc (PRGO) Stock Analysis: Exploring a Potential 50% Upside with a High Dividend Yield

Perrigo Company plc (NYSE: PRGO), a prominent player in the healthcare sector, particularly within the specialty and generic drug manufacturing industry, presents an intriguing opportunity for investors. With its headquarters..

Concentra Group Holdings Parent (CON) Stock Analysis: A Healthcare Play with 41% Upside Potential

Concentra Group Holdings Parent, Inc. (CON), a key player in the healthcare sector, is garnering significant attention from investors seeking robust growth prospects. With a current market capitalization of $2.58..

CRISPR Therapeutics AG (CRSP) Stock Analysis: Exploring a 50.70% Potential Upside in Gene Editing Innovations

CRISPR Therapeutics AG (NASDAQ: CRSP), a pioneering entity in the realm of gene editing, is capturing investor attention with its cutting-edge CRISPR/Cas9 technology. Operating within the biotechnology sector, this Swiss..

Kiniksa Pharmaceuticals (KNSA) Investor Outlook: Exploring a Promising 33% Upside

Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) is capturing investor attention with its impressive growth potential and robust pipeline of novel therapies targeting diseases with unmet medical needs. With a current market..

Alphatec Holdings, Inc. (ATEC) Stock Analysis: A Potential 17% Upside in the Medical Devices Sector

Alphatec Holdings, Inc. (NASDAQ: ATEC) stands out as a compelling player in the healthcare sector, specifically within the dynamic field of medical devices. The company, headquartered in Carlsbad, California, is..

Protagonist Therapeutics, Inc. (PTGX) Stock Analysis: Exploring a 7.47% Potential Upside in the Biotech Sector

Protagonist Therapeutics, Inc. (NASDAQ: PTGX), a prominent player in the biotechnology industry, continues to capture investor attention with its innovative therapeutic developments and significant market presence. With a current market..

CG Oncology, Inc. (CGON) Stock Analysis: Exploring a 77% Potential Upside in Biotech

For investors eyeing the biotechnology sector, CG Oncology, Inc. (NASDAQ: CGON) presents a compelling opportunity. With a market capitalization of $3.22 billion, this Irvine, California-based company specializes in developing innovative..

Alignment Healthcare, Inc. (ALHC) Stock Analysis: A 13% Upside Potential in the Booming Healthcare Plans Sector

Alignment Healthcare, Inc. (NASDAQ: ALHC) is carving a distinctive niche in the healthcare industry with its consumer-centric platform designed to cater to the needs of seniors through Medicare Advantage plans...

Viking Therapeutics, Inc. (VKTX) Stock Analysis: A Biotech Gem with 156% Upside Potential

Viking Therapeutics, Inc. (NASDAQ: VKTX) has emerged as a standout player in the biotechnology sector, capturing the attention of investors with its promising pipeline and significant upside potential. With a..

Amicus Therapeutics, Inc. (FOLD): Exploring 19.5% Revenue Growth and Analyst Consensus in the Biotech Sector

Amicus Therapeutics, Inc. (NASDAQ: FOLD), a prominent player in the biotechnology sector, has been making waves with its focus on rare diseases. As the company continues to expand its footprint..

Mirum Pharmaceuticals, Inc. (MIRM) Stock Analysis: A Biotech Force with 28.54% Potential Upside

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a prominent player in the biotechnology sector, has captured investor attention with its innovative approach to treating rare and orphan diseases. Headquartered in Foster City,..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds